High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification

Table 2 List of the publicly available microarray expression datasets included for the survival analysis

Dataset	GEO accession	Microarray platform	Sample size	FIGO Stage IV	Optimal debulking
Bentink et al. [56]	E.MTAB. 386	Illumina HumanRef-8 v2.0 beadchip	128:128:42	15%	78%
Bonome et al. [57]	GSE26712	Affymetrix HG-U133A Array	185:185:46	20%	49%
Ferriss et al. [58]	GSE30161	Affymetrix HG-U133A Gene Chip array	58:47:38	9%	41%
Tothill et al. [19]	GSE9891	Affymetrix HG-U133 Plus 2.0	260:235:42	9%	61%
TCGA [4]	TCGA	Affymetrix HT HG-U133A	510:503:44	15%	73%
Konecny et al. [20]	Mayo Clinic	Agilent Whole Human Genome 4x44K Expression Arrays	382: 369:41	22%	77%

Six whole transcriptome studies with at least 40 patients were evaluated. Exclusion of samples with missing values for age, stage, histology, grade, debulking status and survival data resulted in 1467 patients for downstream analysis. Sample size column provides the number of available samples: number of included samples: median survival time in months

ISSN: 1756-994X